Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 10/20 | 0.41 |
| ▸ | NCF1 | P14598 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250081 | 0.85 | MAPT (0.35) | CD38NCF1MAPTSMN1; SMN2GAA | |
| SCHEMBL5250243 | 0.71 | CRHR1 (0.53) | CD38SMN1; SMN2 | |
| SCHEMBL5249524 | 0.68 | CRHR1 (0.48) | MAPTSMN1; SMN2 | |
| SCHEMBL5251141 | 0.68 | NCF1 (0.44) | NCF1MAPTSMN1; SMN2GAAHRH4 | |
| SCHEMBL5409567 | 0.67 | CRHR1 (0.38) | KCNH2 | |
| SCHEMBL5248032 | 0.66 | CRHR1 (0.53) | CD38SMN1; SMN2PIK3R2 | |
| SCHEMBL6588228 | 0.65 | MAPT (0.49) | CD38MAPTSMN1; SMN2GAA | |
| SCHEMBL439824 | 0.63 | NR4A2 (0.65) | CD38NCF1MAPTSMN1; SMN2GAA | |
| SCHEMBL5249809 | 0.63 | MAPT (0.57) | CD38MAPTSMN1; SMN2GAAHRH4 | |
| SCHEMBL2284354 | 0.63 | KDM4E (0.62) | MAPTSMN1; SMN2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299378-B1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-7160900-B2 | Tetrahydropyridino or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-6852732-B2 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1299378-A4 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1299378-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | Taisho Pharmaceutical Co. Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002002549-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | CRHR1, CRHR2, VIPR1 | CD38 1069/4885NCF1 2220/4885MAPT 3511/4885 |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | CRHR1, CRHR2, AGTR1 | CD38 866/4885NCF1 1877/4885MAPT 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.